87 related articles for article (PubMed ID: 1335764)
1. Blocking factors (soluble membrane receptors) for tumor necrosis factor and lymphotoxin detected in ascites and released in short-term cultures obtained from ascites and solid tumors in women with gynecologic malignancy.
Grosen EA; Yamamoto RS; Ioli G; Ininns EK; Gatanaga M; Gatanaga T; DiSaia PJ; Berman M; Manetta A; Granger GA
Lymphokine Cytokine Res; 1992 Dec; 11(6):347-53. PubMed ID: 1335764
[TBL] [Abstract][Full Text] [Related]
2. Identification of tumor necrosis factor and lymphotoxin blocking factor(s) in the ascites of patients with advanced and recurrent ovarian cancer.
Cappuccini F; Yamamoto RS; DiSaia PJ; Grosen EA; Gatanaga M; Lucci JA; Ininns EK; Gatanaga T; Granger GA
Lymphokine Cytokine Res; 1991 Jun; 10(3):225-9. PubMed ID: 1653048
[TBL] [Abstract][Full Text] [Related]
3. Measurement of the soluble membrane receptors for tumor necrosis factor and lymphotoxin in the sera of patients with gynecologic malignancy.
Grosen EA; Granger GA; Gatanaga M; Ininns EK; Hwang C; DiSaia P; Berman M; Manetta A; Emma D; Gatanaga T
Gynecol Oncol; 1993 Jul; 50(1):68-77. PubMed ID: 8394276
[TBL] [Abstract][Full Text] [Related]
4. Release of soluble TNF/LT receptors from a human ovarian tumor cell line (PA-1) by stimulation with cytokines in vitro.
Gatanaga M; Grosen EA; Burger RA; Granger GA; Gatanaga T
Lymphokine Cytokine Res; 1993 Aug; 12(4):249-53. PubMed ID: 8218597
[TBL] [Abstract][Full Text] [Related]
5. Role of 55- and 75-kDa tumor necrosis factor membrane receptors in the regulation of intercellular adhesion molecules-1 expression by HL-60 human promyelocytic leukemia cells in vitro.
Abe Y; Gatanaga M; Osuka Y; Kimura S; Burger RA; Granger GA; Gatanaga T
J Immunol; 1993 Jun; 150(11):5070-9. PubMed ID: 8098725
[TBL] [Abstract][Full Text] [Related]
6. Studies on the differing effects of tumor necrosis factor and lymphotoxin on the growth of several human tumor lines.
Browning J; Ribolini A
J Immunol; 1989 Sep; 143(6):1859-67. PubMed ID: 2550545
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of lymphokine-activated T killer cell tumor necrosis factor receptor mRNA transcription, tumor necrosis factor receptor membrane expression, and tumor necrosis factor/lymphotoxin release by IL-1 beta, IL-4, and IL-6 in vitro.
Dett CA; Gatanaga M; Ininns EK; Cappuccini F; Yamamoto RS; Granger GA; Gatanaga T
J Immunol; 1991 Mar; 146(5):1522-6. PubMed ID: 1847164
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic activities of recombinant soluble murine lymphotoxin-alpha and lymphotoxin-alpha beta complexes.
Mackay F; Bourdon PR; Griffiths DA; Lawton P; Zafari M; Sizing ID; Miatkowski K; Ngam-ek A; Benjamin CD; Hession C; Ambrose CM; Meier W; Browning JL
J Immunol; 1997 Oct; 159(7):3299-310. PubMed ID: 9317128
[TBL] [Abstract][Full Text] [Related]
9. Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors.
Browning JL; Dougas I; Ngam-ek A; Bourdon PR; Ehrenfels BN; Miatkowski K; Zafari M; Yampaglia AM; Lawton P; Meier W
J Immunol; 1995 Jan; 154(1):33-46. PubMed ID: 7995952
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin (LT) on human T lymphocytes. TNF and LT differ in their receptor binding properties and the induction of MHC class I proteins on a human CD4+ T cell hybridoma.
Andrews JS; Berger AE; Ware CF
J Immunol; 1990 Apr; 144(7):2582-91. PubMed ID: 1969453
[TBL] [Abstract][Full Text] [Related]
11. Identification of TNF-LT blocking factor(s) in the serum and ultrafiltrates of human cancer patients.
Gatanaga T; Lentz R; Masunaka I; Tomich J; Jeffes EW; Baird M; Granger GA
Lymphokine Res; 1990; 9(2):225-9. PubMed ID: 2187118
[TBL] [Abstract][Full Text] [Related]
12. Functional discrepancies between tumor necrosis factor and lymphotoxin alpha explained by trimer stability and distinct receptor interactions.
Schuchmann M; Hess S; Bufler P; Brakebusch C; Wallach D; Porter A; Riethmüller G; Engelmann H
Eur J Immunol; 1995 Aug; 25(8):2183-9. PubMed ID: 7664782
[TBL] [Abstract][Full Text] [Related]
13. Minimal tumor necrosis factor receptor binding protein: optimum biological activity of a truncated p55 soluble tumor necrosis factor receptor-IgG fusion protein.
Corcoran AE; Scallon BJ; Trinh H; Chernajovsky Y; Ghrayeb J; Feldmann M
Eur Cytokine Netw; 1998 Sep; 9(3):255-62. PubMed ID: 9831174
[TBL] [Abstract][Full Text] [Related]
14. Signaling through the lymphotoxin-beta receptor stimulates HIV-1 replication alone and in cooperation with soluble or membrane-bound TNF-alpha.
Marshall WL; Brinkman BM; Ambrose CM; Pesavento PA; Uglialoro AM; Teng E; Finberg RW; Browning JL; Goldfeld AE
J Immunol; 1999 May; 162(10):6016-23. PubMed ID: 10229841
[TBL] [Abstract][Full Text] [Related]
15. Multiple sclerosis: expression of molecules of the tumor necrosis factor ligand and receptor families in relationship to the demyelinated plaque.
Raine CS; Bonetti B; Cannella B
Rev Neurol (Paris); 1998 Sep; 154(8-9):577-85. PubMed ID: 9809372
[TBL] [Abstract][Full Text] [Related]
16. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.
Mohler KM; Torrance DS; Smith CA; Goodwin RG; Stremler KE; Fung VP; Madani H; Widmer MB
J Immunol; 1993 Aug; 151(3):1548-61. PubMed ID: 8393046
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of action of the tumor necrosis factor and lymphotoxin ligand-receptor system.
Warzocha K; Bienvenu J; Coiffier B; Salles G
Eur Cytokine Netw; 1995; 6(2):83-96. PubMed ID: 7578992
[TBL] [Abstract][Full Text] [Related]
18. Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1 species.
Pober JS; Lapierre LA; Stolpen AH; Brock TA; Springer TA; Fiers W; Bevilacqua MP; Mendrick DL; Gimbrone MA
J Immunol; 1987 May; 138(10):3319-24. PubMed ID: 3494766
[TBL] [Abstract][Full Text] [Related]
19. Differences in the bioactivity of recombinant human TNF, LT, and T-cell-derived LT-3 on transformed cells in vitro and the Meth A tumor growing in BALB/c mice.
Granger GA; Masunaka I; Averbook B; Kobayashi M; Fitzgerald M; Yamamoto R
J Biol Response Mod; 1988 Oct; 7(5):488-97. PubMed ID: 3263472
[TBL] [Abstract][Full Text] [Related]
20. Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes.
Browning JL; Sizing ID; Lawton P; Bourdon PR; Rennert PD; Majeau GR; Ambrose CM; Hession C; Miatkowski K; Griffiths DA; Ngam-ek A; Meier W; Benjamin CD; Hochman PS
J Immunol; 1997 Oct; 159(7):3288-98. PubMed ID: 9317127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
